Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
CEPHALEXIN CAPSULES, USP AND CEPHALEXIN FOR ORAL SUSPENSION, USPRx only
Medication labelWhy this: Advisory · dailymed-prescription
To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules and cephalexin for oral suspension and other antibacterial drugs, cephalexin capsules and cephalexin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by S. pneumoniae and S. pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to S. pneumoniae, H. influenzae, staphylococci, streptococci and M. catarrhalis Skin and skin structure infections caused by staphylococci and/or streptococci Bone infections caused by staphylococci and/or P. mirabilis Genitourinary tract infections, including acute prostatitis, caused by E. coli, P. mirabilis, and K. pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated.
- generic_name
- cephalexin
- product_names
- CEPHALEXIN
- ndc
- 63304-656, 63304-656-27, 63304-656-01, 63304-656-05, 63304-657, 63304-657-27, 63304-657-01, 63304-657-05, 63304-958, 63304-958-01, 63304-958-02, 63304-959, 63304-959-01, 63304-959-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en